Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: $INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inovio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inovio Pharmaceuticals's position in the market.
Rhea-AI Summary
INOVIO (NASDAQ:INO) has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. The grant includes restricted stock units (RSUs) covering 3,750 shares of common stock and an option to purchase 5,833 shares of common stock. The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second, and third anniversaries of the Grant Date. The stock option has an exercise price of $5.39, the closing price of INOVIO's common stock on the Grant Date. The vesting of the RSUs and stock option is subject to the employee's continued employment with INOVIO on the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
-
Rhea-AI Summary
INOVIO announces a 1-for-12 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of issued and outstanding shares from approximately 280.1 million to approximately 23.3 million, with no change in the par value per share. Fractional shares will not be issued, and stockholders entitled to receive a fractional share will receive a cash payment. The reverse stock split will not reduce the number of authorized shares of the company's common stock, which will remain at 600,000,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.15%
Tags
-
Rhea-AI Summary
INOVIO to participate in a virtual fireside chat to discuss potential treatment of Recurrent Respiratory Papillomatosis (RRP) with key panel participants including Dr. Jacqueline Shea, Dr. Michael Sumner, and Dr. Simon Best. The event will be moderated by Hartaj Singh of Oppenheimer & Co. Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
-
Rhea-AI Summary
INOVIO (NASDAQ: INO) plans to submit a Biological License Application (BLA) for INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), in the second half of 2024. The company aims to request a Priority Review from the FDA, with plans to launch INO-3107 in 2025. If approved, it would be the first DNA medicine for RRP patients in the US and INOVIO's first approved product. The company has already received Orphan Drug and Breakthrough Therapy designations from the FDA, as well as Orphan Drug designation from the European Commission. INOVIO's delivery device, CELLECTRA®, has also received CE marking. The request for Rolling Submission and Priority Review aims to expedite the review process, potentially shortening the FDA's review timeline to approximately six months from the time of submission acceptance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary
INO Achieves Breakthrough Therapy Designation for INO-3107, Accelerates Commercialization Strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
Rhea-AI Summary
INOVIO has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. The grant consists of an option to purchase 15,625 shares of common stock at an exercise price of $0.36, the closing price on the grant date. The option will vest over a period of four years, with one-fourth of the shares vesting on the grant date and an additional one-fourth vesting on each anniversary of the grant date. The employee's continued employment with INOVIO is required for the option to vest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Summary
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary
INOVIO receives FDA feedback on Phase 1/2 trial of INO-3107 for RRP, no Phase 3 trial required for BLA submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
Rhea-AI Summary
Geneos Therapeutics completes Series A3 financing round with an additional $5 million investment, totaling $10 million. Shanghai Healthcare Capital joins as an investor. Proceeds will fund completion of Phase 1b/2a GT-30 trial of personalized therapeutic cancer vaccine in liver cancer. Top-line data expected by end of year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Inovio Pharmaceuticals, Inc.
Nasdaq:INO
INO Rankings
INO Stock Data
287.87M
22.99M
1.61%
17.98%
9%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
United States of America
SAN DIEGO
About INO
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.